110 related articles for article (PubMed ID: 8848823)
21. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
[TBL] [Abstract][Full Text] [Related]
22. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
23. Different effects of desipramine on bufuralol 1''-hydroxylation by rat and human CYP2D enzymes.
Isobe T; Hichiya H; Hanioka N; Yamamoto S; Shinoda S; Funae Y; Satoh T; Yamano S; Narimatsu S
Biol Pharm Bull; 2005 Apr; 28(4):634-40. PubMed ID: 15802801
[TBL] [Abstract][Full Text] [Related]
24. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
25. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
[TBL] [Abstract][Full Text] [Related]
26. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
[TBL] [Abstract][Full Text] [Related]
27. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
28. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
[TBL] [Abstract][Full Text] [Related]
29. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
30. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Khan AY; Preskorn SH; Horst WD
J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.
Harris RZ; Salfi M; Posvar E; Hoelscher D; Padhi D
Eur J Clin Pharmacol; 2007 Feb; 63(2):159-63. PubMed ID: 16680561
[TBL] [Abstract][Full Text] [Related]
32. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
Philip PA; James CA; Rogers HJ
Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
[TBL] [Abstract][Full Text] [Related]
33. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
34. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
Shimoda K; Morita S; Hirokane G; Yokono A; Someya T; Takahashi S
Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
[TBL] [Abstract][Full Text] [Related]
36. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
Cooke RG; Warsh JJ; Stancer HC; Reed KL; Persad E
Clin Pharmacol Ther; 1984 Sep; 36(3):343-9. PubMed ID: 6467794
[TBL] [Abstract][Full Text] [Related]
37. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
38. The effect of moderate hemodilution with Fluosol on cytochrome P4502D6 activity in the rat.
Shrewsbury RP; Oliver SR; White LG
Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):1237-42. PubMed ID: 7849928
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
40. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
